The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia

摘要

BackgroundIn Australia, government-subsidised access to high-cost medicines is "targeted" to particular sub-sets of patients under the Pharmaceutical Benefits Scheme to achieve cost-effective use. In order to determine how this access system could be improved, the opinions of key stakeholders on access to biological agents for rheumatoid arthritis were explored.